INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

Showing studies that examined garlic. Clear

People assigned to a diet, food or program and measured.

5 studies

2023 / Single-center, prospective, randomized, single-blind clinical trial

Rosuvastatin reduced LDL-C significantly more than placebo and six dietary supplements, none of which lowered LDL-C compared with placebo.

Adults with an increased 10-year risk of ASCVD were randomized to rosuvastatin 5 mg daily, placebo, fish oil, cinnamon, garlic, turmeric, plant sterols, or red yeast rice for 28 days. A total of 190 participants completed the trial. Rosuvastatin achieved a greater percent LDL-C reduction than all supplements and placebo (P < 0.001), with a -35.2% difference compared with placebo (95% CI: -41.3% to -29.1%; P < 0.001). None of the dietary supplements demonstrated a significant decrease in LDL-C compared with placebo, and adverse event rates were similar across groups.

Laffin LJ, Bruemmer D, Garcia M, et al. J Am Coll Cardiol, 2023. PMID 36351465

2017 / Randomized controlled trial

Garlic supplementation improved brachial endothelial function in coronary artery disease patients.

Patients with coronary artery disease were randomized to receive garlic powder or dummy pills twice each day across a 3-month period. Ultrasound evaluation showed that flow-mediated dilation improved by 50.7% in the garlic group compared to the control group (p = 0.016). High-sensitivity C-reactive protein declined significantly with garlic but did not differ from control, and no alterations occurred in macrophage cholesterol efflux or mononuclear cell gene expression.

Mahdavi-Roshan M, Mirmiran P, Arjmand M, et al. Anatol J Cardiol, 2017. PMID 28554988

2016 / Randomized crossover trial

Aged garlic extract did not improve endothelial function or insulin resistance in diabetes

A randomized crossover pilot trial evaluated 26 adults with type 2 diabetes who consumed 1,200 mg of aged garlic extract or placebo daily for 4 weeks. Supplementation had no significant effect on insulin resistance or metabolic measures. In addition, aged garlic extract did not significantly alter markers of endothelial function, oxidative stress, or vascular inflammation in this high-risk population.

Atkin M, Laight D, Cummings MH J Diabetes Complications, 2016. PMID 26954484

2013 / Randomized controlled trial

Garlic powder tablets slowed carotid intima-media thickness progression compared to placebo in CAD.

In a trial of 56 patients with coronary artery disease, participants received garlic powder tablets or placebo twice daily for 3 months. Garlic resulted in minor intima-media thickness variation (-0.009 ± 0.007 mm), whereas placebo showed an increase (0.04 ± 0.01 mm), reflecting a significant between-group divergence (p < 0.001). Lipid and lipoprotein concentrations did not differ significantly between treatments.

Mahdavi-Roshan M, Zahedmehr A, Mohammad-Zadeh A, et al. Nutr Health, 2013. PMID 25573347

1993 / Randomized controlled trial

A 12-week regimen of garlic powder tablets increased walking distance in patients with stage II peripheral arterial occlusive disease.

Patients with stage II peripheral arterial occlusive disease received either 800 mg of garlic powder daily or a placebo for 12 weeks, with both groups undergoing physical therapy twice weekly. The increase in walking distance was significantly higher (P < 0.05) in the garlic group (by 46 m, from 161.0 +/- 65.1 to 207.1 +/- 85.0 m) compared with the placebo group (by 31 m, from 172.0 +/- 60.9 to 203.1 +/- 72.8 m). Diastolic blood pressure, spontaneous thrombocyte aggregation, plasma viscosity, and cholesterol concentration also decreased significantly, while body weight was maintained. The garlic-specific increase in walking distance did not appear until the 5th week of treatment, coinciding with a decrease in spontaneous thrombocyte aggregation.

Kiesewetter H, Jung F, Jung EM, et al. Clin Investig, 1993. PMID 8508009